Diabetic Eye Disease Viewpoint Ang2 inhibition for retinal disease Carl Zeiss Case Studies Retina in 2020 Updates From Angiogenesis 2021

Diabetic Eye Disease Viewpoint Ang2 inhibition for retinal disease Carl Zeiss Case Studies Retina in 2020 Updates From Angiogenesis 2021

View More Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Medical World News

Updates From Angiogenesis 2021

Medical World News Podcasts Rapid Readouts Updates From Angiogenesis 2021 Viewpoints

Digital Edition

Supplements And Featured Publications

Digital Edition Supplements And Featured Publications

Conferences CME/CE

Sponsored Resources

Zeiss Case Studies

Sponsored Resources Zeiss Case Studies

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Diabetic Eye Disease Viewpoint
Ang2 inhibition for retinal disease
Carl Zeiss Case Studies
Retina in 2020
Updates From Angiogenesis 2021

ClinicalSee All >

Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Opthalmology Times Europe. All rights reserved.

New therapy enters trials

July 8, 2008

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

Related Content:

ArticlesGlaucoma

Using pivotal study data to guide glaucoma patient management decisions

Using pivotal study data to guide glaucoma patient management decisions

Johnson + Johnson's TECNIS Eyhance Toric II IOL launches in Europe

Johnson + Johnson's TECNIS Eyhance Toric II IOL launches in Europe

Posterior corneal elevation: Is there a role for premium IOLs?

Posterior corneal elevation: Is there a role for premium IOLs?